Usage: Epclusa treats chronic hepatitis C virus (HCV) genotypes 1–6 in adults and children aged 3 and older. It is used with or without cirrhosis; patients with decompensated cirrhosis take it in combination with ribavirin.
Usage: EVOTAZ combines atazanavir (HIV-1 protease inhibitor) and cobicistat (CYP3A inhibitor) for treating HIV-1 infection in adults and pediatric patients weighing at least 35 kg, used alongside other antiretroviral agents. Treatment-experienced patients should be guided by baseline protease inhibitor resistance substitutions.
Usage: Genvoya is a complete HIV-1 treatment regimen for adults and children weighing at least 25 kg, used in treatment-naive patients or to replace current therapy in those virologically suppressed on stable antiretrovirals for at least 6 months with no treatment failure or resistance history.
Usage: Lupkynis is indicated, alongside background immunosuppressive therapy, for the treatment of active lupus nephritis in adults. Not recommended in combination with cyclophosphamide.
Usage: Mavyret treats acute or chronic hepatitis C (genotypes 1–6) in adults and children 3+ without cirrhosis or with compensated cirrhosis. Also indicated for genotype 1 patients previously treated with an NS5A inhibitor or NS3/4A protease inhibitor (but not both).
Usage: Prevymis prevents cytomegalovirus (CMV) infection and disease in CMV-seropositive adults and children (6 months+, ≥6 kg) receiving an allogeneic stem cell transplant, and in adults and adolescents (12 years+, ≥40 kg) who are high-risk kidney transplant recipients (CMV-positive donor, CMV-negative recipient).
Usage: Prezcobix and Prezcobix Ped are used with other antiretrovirals to treat HIV-1 in treatment-naïve and treatment-experienced adults and pediatric patients 3 years and older weighing at least 15 kg with no darunavir resistance-associated substitutions.
Usage: REZDIFFRA is used with diet and exercise to treat adults with noncirrhotic NASH and moderate-to-advanced liver fibrosis (stages F2–F3). Approved under accelerated approval. Not for use in patients with decompensated cirrhosis.